Trial Profile
A Randomized, Double-Blind, Parallel-Group,Multicenter, Dose-Response, Vehicle-Controlled Study of the Safety and Efficacy of NB-002 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Cetylpyridinium (Primary)
- Indications Onychomycosis
- Focus Therapeutic Use
- Sponsors BlueWillow Biologics; NanoBio Corporation
- 07 May 2018 According to a BlueWillow Biologics media release, NanoBio Corporation has changed its name to BlueWillow Biologics.
- 15 May 2014 New trial record